Search

Objective To evaluate treatment response, survival, and the associations between KRASmutation status and tumour expression levels of BRCA1, TYMSand SRCretrospectively in a cohort of patients with non-small cell lung cancer (NSCLC), treated exclusively with conjunctive platinum-based doublet chemotherapy.Methods KRASmutation status was determined via amplification refractory mutation and multiple quantitative polymerase chain reaction (PCR) analysis. Tumour expression levels of BRCA1, TYMSand SRCwere determined via real time quantitative PCR.Results Patients with KRASmutations (n= 3) had significantly shorter survival duration than patients with wild type KRAS(n= 42). Tumour expression levels of BRCA1and TYMS, but not SRC, were significantly lower in patients with, than in those without, KRASmutations. Tumour expression level of BRCA1was positively correlated with survival duration.Conclusions KRASmutation status and BRCA1tumour expression are potential biomarkers for tailoring chemotherapy and predicting clinical outcome.